-
1.发明申请公开(公告)号：US20080108591A1
公开(公告)日：2008-05-08
申请号：US11979140
申请日：2007-10-31
CPC分类号： A61K31/53 , A61K31/58 , C07D251/10 , C07D251/52 , C07D251/72
摘要： The invention relates to the compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined in claim 1. These compounds can be used in the treatment of pathological conditions associated with the insulin-resistance syndrome.
摘要翻译： 本发明涉及通式（I）的化合物：其中R 1，R 2，R 3，R 4，R 5和R 6如权利要求1中所定义。这些化合物可用于治疗与胰岛素抵抗相关的病理状况 综合征
-
2.发明授权公开(公告)号：US07034021B2
公开(公告)日：2006-04-25
申请号：US10181223
申请日：2001-01-25
IPC分类号： C07D251/10 , A61K31/53 , A61P3/06 , A61P3/10
CPC分类号： A61K31/53 , A61K31/58 , C07D251/10 , C07D251/52 , C07D251/72
摘要： The invention concerns compounds of general formula (I) wherein: R1, R2, R3, R4, R5 and R6 are as defined in Claim 1. Said compounds are useful in the treatment of pathologies related to the insulin-resistance syndrome.
摘要翻译： 本发明涉及通式（I）的化合物，其中：R 1，R 2，R 3，R 4，R 5和R 6如权利要求1中所定义。所述化合物可用于治疗与胰岛素抵抗综合征相关的病理学。
-
3.发明申请公开(公告)号：US20050165022A1
公开(公告)日：2005-07-28
申请号：US11085145
申请日：2005-03-22
IPC分类号： C07D251/18 , A61K20060101 , A61K31/53 , A61K31/5377 , A61K31/541 , A61K31/58 , A61P20060101 , A61P3/10 , A61P5/50 , A61P7/12 , A61P9/00 , A61P9/10 , A61P13/12 , A61P25/00 , A61P25/28 , C07D20060101 , C07D251/10 , C07D251/52 , C07D251/72 , C07D403/04 , C07D405/04 , C07D413/02 , C07D417/02 , C07D471/10 , C07D491/107 , C07J71/00 , C07D251/48 , C07D43/02
CPC分类号： A61K31/53 , A61K31/58 , C07D251/10 , C07D251/52 , C07D251/72
摘要： The invention concerns compounds of general formula (I) wherein: R1, R2, R3, R4, R5 and R6 are as defined in Claim 1. The compounds are useful in the treatment of pathologies related to the insulin-resistance syndrome.
摘要翻译： 本发明涉及通式（I）的化合物，其中：R 1，R 2，R 3，R 4，R 5和R 6如权利要求1中所定义。该化合物可用于治疗与胰岛素抵抗综合征相关的病理学。
-
4.发明授权4-(1-piperazinyl) benzoic acid derivatives, process for preparing them and their therapeutic applications 失效4-（1-哌嗪基）苯甲酸衍生物，其制备方法及其治疗应用公开(公告)号：US06281215B1
公开(公告)日：2001-08-28
申请号：US09331155
申请日：1999-10-20
IPC分类号： A61K31495
CPC分类号： C07D295/15 , C07D215/08 , C07D307/52
摘要： New 4-(1-piperazinyl)benzoic acid derivatives of the formula (I) are described. Also described is methods for making these compounds and their use as therapeutic agents. In particular, the compounds find use in the treatment of diabetes.
摘要翻译： 描述了式（I）的新的4-（1-哌嗪基）苯甲酸衍生物。 还描述了制备这些化合物及其作为治疗剂的用途的方法。 特别地，这些化合物可用于治疗糖尿病。
-
5.发明授权Antidiabetic piperazine derivatives, processes for their preparation and compositions containing them 失效抗糖尿病哌嗪衍生物，其制备方法和含有它们的组合物公开(公告)号：US06376495B1
公开(公告)日：2002-04-23
申请号：US09744693
申请日：2001-01-29
IPC分类号： A61K31495
CPC分类号： C07D239/42 , C07D213/74 , C07D277/82 , C07D295/088
摘要： Piperazine derivatives of formula (I) wherein Z, X, n, Ar and i have the meanings defined herein are usefull in the treatment of pathologies associated with insulin-resistance syndrome.
摘要翻译： 式（I）的哌嗪衍生物其中Z，X，n，Ar和i具有本文定义的含义，可用于治疗与胰岛素抵抗综合征相关的病理学。
-
公开(公告)号：US6143787A
公开(公告)日：2000-11-07
申请号：US230849
申请日：1999-02-02
IPC分类号： A61K31/19 , A61K31/192 , A61K31/341 , A61K31/357 , A61K31/36 , A61P3/10 , C07C59/84 , C07C59/86 , C07C59/88 , C07C59/90 , C07C69/738 , C07C69/86 , C07C69/90 , C07D307/16 , C07D307/77 , C07D317/60
CPC分类号： C07D317/60 , C07C59/84 , C07C69/738 , C07D307/16
摘要： The present invention relates to a pharmaceutical composition comprising, as active principle, a compound of formula: ##STR1## in which the groups A and B are chosen, independently of each other, from: a mono-, bi- or tricyclic aryl group having from 6 to 14 carbon atoms;a heteroaromatic group chosen from pyridyl, pyrimidyl, pyrrolyl, furyl and thienyl groups;an alkyl group having from 1 to 14 carbon atoms;a cycloalkyl group having from 5 to 8 carbon atoms;a saturated heterocyclic group chosen from tetrahydrofuryl, tetrahydropyranyl, piperidyl and pyrrolidinyl groups;to its solvate or to a salt of this acid with a pharmaceutically acceptable base.Figures: none.
摘要翻译： PCT No.PCT / EP97 / 04252 Sec。 371日期1999年2月2日 102（e）1999年2月2日PCT PCT 1997年8月5日PCT公布。 公开号WO98 / 07681 日期：1998年2月26日本发明涉及一种药物组合物，其包含作为活性成分的下式化合物：其中A和B组彼此独立地选自：单 - ，二 - 或三环芳基 具有6至14个碳原子的基团; 选自吡啶基，嘧啶基，吡咯基，呋喃基和噻吩基的杂芳基; 具有1至14个碳原子的烷基; 具有5至8个碳原子的环烷基; 选自四氢呋喃基，四氢吡喃基，哌啶基和吡咯烷基的饱和杂环基; 至其溶剂化物或该酸的盐与药学上可接受的碱。 数字：无。
-
7.发明授权2-adamantyl-butyramide derivatives as selective 11β-HSD1 inhibitors 有权2-金刚烷基 - 丁酰胺衍生物作为选择性11＆amp; -HSD1抑制剂公开(公告)号：US08183265B2
公开(公告)日：2012-05-22
申请号：US12520141
申请日：2007-11-22
IPC分类号： A01N43/80 , A01N43/40 , A61K31/42 , A61K31/44 , C07D261/00 , C07D413/00 , C07D413/04
CPC分类号： C07D413/04 , C07C233/06 , C07C233/08 , C07C233/13 , C07C233/15 , C07C233/23 , C07C233/26 , C07C235/14 , C07C235/22 , C07D207/27 , C07D213/40 , C07D213/75 , C07D271/06 , C07D277/46 , C07D295/18 , C07D295/185
摘要： The present invention relates to 2-adamantyl-butyramide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
摘要翻译： 本发明涉及式I的2-金刚烷基 - 丁酰胺衍生物作为酶1-β-羟基类固醇脱氢酶1型（11＆amp; -HSD-1）的选择性抑制剂，以及这些化合物用于治疗和预防代谢综合征 糖尿病，胰岛素抵抗，肥胖症，脂质障碍，青光眼，骨质疏松症，认知障碍，焦虑症，抑郁症，免疫疾病，高血压等疾病和病症。
-
8.发明授权公开(公告)号：US07767676B2
公开(公告)日：2010-08-03
申请号：US11976936
申请日：2007-10-30
IPC分类号： C07D251/48 , A61K31/53 , A61P3/06 , A61P3/10 , A61P3/04 , A61P9/02 , A61P9/10 , A61P13/12 , A61P25/28
CPC分类号： A61K31/53 , A61K31/58 , C07D251/10 , C07D251/52 , C07D251/72
摘要： The invention relates to the compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined in Claim 1. These compounds can be used in the treatment of pathological conditions associated with the insulin-resistance syndrome.
摘要翻译： 本发明涉及通式（I）的化合物：其中R 1，R 2，R 3，R 4，R 5和R 6如权利要求1中所定义。这些化合物可用于治疗与胰岛素抵抗相关的病理状况 综合征
-
9.发明授权(Aminoiminomethyl) amino) alkane-carboxamides and their applications in therapy 有权（（氨基亚氨基甲基）氨基）烷酰胺及其在治疗中的应用公开(公告)号：US06518458B1
公开(公告)日：2003-02-11
申请号：US09869957
申请日：2001-07-10
IPC分类号： C07C23305
CPC分类号： C07D213/75 , C07C279/14 , C07C2601/16 , C07D295/185
摘要： The invention to a pharmaceutical composition comprising as active principle a compound of general formula (I), in which R1, R2, R3, and A are as defined in claim 1. These compositions can be used in the treatment of pathologies associated with insulin resistance syndrome.
摘要翻译： 本发明涉及包含作为活性成分的通式（I）化合物的药物组合物，其中R 1，R 2，R 3和A如权利要求1所定义。这些组合物可用于治疗与胰岛素抵抗相关的病理学 综合征
-
公开(公告)号：US06437143B1
公开(公告)日：2002-08-20
申请号：US09202076
申请日：1998-12-07
申请人： Gérard Moinet , Gérard Botton , Etienne Prugnard , Liliane Doare , Micheline Kergoat , Didier Mesangeau
发明人： Gérard Moinet , Gérard Botton , Etienne Prugnard , Liliane Doare , Micheline Kergoat , Didier Mesangeau
IPC分类号： C07D27734
摘要： The present invention relates to the field of chemistry and more particularly to that of therapeutic chemistry. The subject of the present invention is more precisely new 5-phenoxyalkyl-2,4-thiazolidinediones of general formula I: in which A represents a linear or branched alkylene group comprising from 2 to 16 carbon atoms D represents a homo- or heterocarbon mono-, di- or tricyclic aromatic structure which may include one or more heteroatoms X represents the substituent of the aromatic structure and is as defined in Claim 1 n is an integer ranging from 1 to 3 with the proviso that if A represents a butyl radical, does not represent the 4-chlorophenyl group. The invention also relates to the tautomeric forms, to the enantiomers, diastereoisomers and epimers of the compounds of general formula I, in free or salified form. The present invention also relates to the processes for producing the compounds of general formula I, their use as antidiabetic agents, and in the treatment of the metabolic syndrome of insulin resistance, as well as the pharmaceutical compositions which contain the compounds of general formula I.
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.019 秒)
